Ambrx

Ambrx is a biopharmaceutical company based in San Diego, California, that specializes in the development of engineered protein therapeutics. The company was founded in 2003 and built its platform around the technology of incorporating non-natural amino acids into proteins — often described as an expanded genetic code — which allows precise site-specific conjugation of drugs, polymers, or other molecules. This approach is used to create antibody-drug conjugates (ADCs), long-acting protein therapeutics, and bispecific or targeted biologics. Ambrx has advanced a pipeline of product candidates in oncology and other therapeutic areas, including ARX788, an anti-HER2 antibody-drug conjugate developed with partners in China, and earlier programs such as ARX201 for growth hormone deficiency. The company has collaborated with larger pharmaceutical firms, including Bristol Myers Squibb, Merck, and others, to apply its protein engineering platform. Ambrx was previously listed on the New York Stock Exchange under the ticker AMAM. In 2024, it was acquired by Jiangsu Hengrui Pharmaceuticals, a major Chinese pharmaceutical company, and became a subsidiary. The company continues to operate as a biopharmaceutical research and development organization, with its headquarters in San Diego and activities extending into global markets, particularly China. As a corporate brand, Ambrx represents both the company and its technology platform for site-specific protein modification. Its identity is closely tied to its scientific approach rather than to consumer products, and it is known primarily within the biotechnology and pharmaceutical industry.

Ambrx was founded in 2003 in San Diego, California, as a biotechnology company focused on expanding the genetic code of living organisms to enable the incorporation of non-natural amino acids into proteins. This technology, sometimes called ReCODE, allows for site-specific modification of proteins, which can improve their therapeutic properties, such as half-life, stability, and targeted delivery. In its early years, Ambrx established collaborations with major pharmaceutical companies. It worked with Merck on the development of engineered protein therapeutics and with Bristol Myers Squibb on antibody-drug conjugates. The company also advanced its own pipeline, including ARX201, a long-acting growth hormone candidate, and ARX788, an anti-HER2 antibody-drug conjugate for HER2-positive cancers. Ambrx went public on the New York Stock Exchange under the ticker AMAM. The company faced challenges common to clinical-stage biotechs, including the need for substantial capital to advance its pipeline. In 2024, Ambrx was acquired by Jiangsu Hengrui Pharmaceuticals, a leading Chinese pharmaceutical company. The acquisition was valued at approximately $1 billion and aimed to strengthen Hengrui's oncology and biologics portfolio. Following the acquisition, Ambrx became a subsidiary and continues to operate from San Diego, with its technology and pipeline integrated into Hengrui's global research and development efforts. The company's history reflects the broader trend of Chinese pharmaceutical companies acquiring innovative Western biotech firms to gain access to novel platforms and product candidates.

• 2024

  Acquired by Jiangsu Hengrui Pharmaceuticals and became a subsidiary.

• 2003

  Ambrx founded in San Diego, California.

Clinical-stage biopharmaceutical company leveraging expanded genetic code technology for site-specific protein conjugation.

• ARX788

  Anti-HER2 antibody-drug conjugate for HER2-positive cancers.

• ARX201

  Long-acting growth hormone candidate for growth hormone deficiency.

1. 1Ambrx (United States) - Wikidatawikidata.org